GNSN Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Consistent Revenue GrowthGenus has exhibited consistent top-line growth and operational efficiency over recent periods, indicating sustained demand for its genetics and services. That pattern supports predictable revenue streams from recurring customer replacements and licensing, underpinning medium-term cash generation.
Stable Capital StructureA moderate debt-to-equity profile and stable equity ratio point to a balanced financing mix that preserves financial flexibility. This reduces refinancing pressure and supports continued R&D and investment in breeding programs without excessive leverage risk over the next several quarters.
Strategic Corporate ActionsRecent board appointments and a clear FY26 outlook reflect active governance and strategic alignment. These corporate actions can strengthen execution of R&D and market expansion plans, improving long-term competitiveness and signaling management focus on scalable, durable growth initiatives.
Bears Say
Volatile Free Cash FlowAlthough operating cash generation is healthy, FCF volatility indicates uneven cash conversion and timing risks from capital needs or working capital swings. This can constrain reinvestment, dividend consistency, or debt reduction over several quarters and limits margin of safety.
Relatively Low Net MarginDespite strong gross margins and operational efficiency, low net margins suggest pressures from SG&A, R&D spend, or other non-operating items. Sustained low net profitability reduces retained earnings available for growth initiatives and increases sensitivity to revenue shocks.
Industry Biosecurity & Market CyclicalityGenus's revenues are structurally tied to livestock health cycles, biosecurity events, and global production scales. These external, industry-level risks can cause multi-month demand swings for genetics and services, making earnings and utilization inherently cyclical and less predictable.
Genus plc News
GNSN FAQ
What was Genus PLC’s price range in the past 12 months?
Currently, no data Available
What is Genus PLC’s market cap?
Genus PLC’s market cap is $34.86B.
When is Genus PLC’s upcoming earnings report date?
Genus PLC’s upcoming earnings report date is Sep 10, 2026 which is in 40 days.
How were Genus PLC’s earnings last quarter?
Genus PLC released its earnings results on Feb 26, 2026. The company reported $14.033 earnings per share for the quarter, beating the consensus estimate of $10.547 by $3.486.
Is Genus PLC overvalued?
According to Wall Street analysts Genus PLC’s price is currently Undervalued.
Does Genus PLC pay dividends?
Genus PLC does not currently pay dividends.
What is Genus PLC’s EPS estimate?
Genus PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Genus PLC have?
Genus PLC has 66,539,440 shares outstanding.
What happened to Genus PLC’s price movement after its last earnings report?
Genus PLC reported an EPS of $14.033 in its last earnings report, beating expectations of $10.547. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Genus PLC?
Currently, no hedge funds are holding shares in MX:GNSN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Genus plc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$654.72 (― Upside)
$654.72 (― Upside)
Blogger Sentiment
Bullish
MX:GNSN Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $659.9K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-10.88%
12-Months-Change
Fundamentals
Return on Equity
1.60%
Trailing 12-Months
Asset Growth
-6.55%
Trailing 12-Months
Company Description
Genus PLC
Genus plc is a global animal genetics company with operations spanning North America, Latin America, the UK, continental Europe, the Middle East, Russia, Africa, and Asia. The business is divided into three key segments: Genus PIC, Genus ABS, and Genus Research and Development. Under its PIC brand, the company provides breeding stock, including sows, boars, and semen, to develop pigs with specific characteristics optimized for pork production. Similarly, for cattle, its ABS, Genus, and Bovec brands offer bull semen and embryos designed to produce calves with advantageous traits for either milk or beef output. Farmers also benefit from a range of specialized technical services, such as semen sexing and reproductive solutions. Genus plc is also strategically collaborating with Beijing Capital Agribusiness Co. Ltd on the research, development, and regulatory approval of porcine reproductive and respiratory syndrome virus (PRRSV)-resistant pigs in China. The company was established in 1994 and is based in Basingstoke, United Kingdom.